FDA Advisory Panel To Review Theratechnologies' NDA For Tesamorelin On May 27 - Quick Facts

Theratechnologies (TH.TO) today announced that the U.S. Food and Drug Administration has confirmed that the Endocrinologic and Metabolic Drugs Advisory Committee will meet to review Theratechnologies' New Drug Application ("NDA") for tesamorelin on Thursday, May 27, 2010.

Theratechnologies submitted an NDA to the FDA on May 29, 2009 for tesamorelin, an analogue of the human growth hormone releasing factor proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA filed the NDA on August 12, 2009, which initiated a substantive review of the application.

The advisory committee meeting was originally scheduled for February 24, 2010, but was postponed due to administrative delays at the FDA. As a result of the postponement, the FDA has indicated that the action goal date, which is the target date for the FDA to complete its review of the tesamorelin NDA, will be extended to July 27, 2010.

For comments and feedback contact: editorial@rttnews.com

Follow RTT